A 股每股现金红利0.85元 证券代码：603297 证券简称：永新光学 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/13 | － | 2025/6/16 | 2025/6/16 | | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经宁波永新光学股份有限公司（以下简称"公司"）2025 年 5 月 20 日 的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，扣除拟回购注销的限制性股票 213,800 股 后，在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股东。 根据公司 2024 年年度股东大会审议通过的《2024 年度利润分配 ...

国浩律师（上海）事务所 专项核查意见 国浩律师（上海）事务所 关于宁波永新光学股份有限公司 差异化权益分派事项的专项核查意见 致：宁波永新光学股份有限公司 国浩律师（上海）事务所接受宁波永新光学股份有限公司（以下简称为"永新光 学"或"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》（以下简称"《回购指引》"）等有关法律法规以及 《宁波永新光学股份有限公司章程》（以下简称"《公司章程》"）的规定，按照律师 行业公认的业务标准，道德规范和勤勉尽责的精神，对永新光学差异化权益分派事 项进行了核查并出具本专项核查意见。 对本专项核查意见的出具，本所律师特作如下声明： 1、本所及经办律师依据《公司法》《证券法》《回购指引》等规定及本专项核查 意见出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责 和诚实信用原则，进行了充分的核查验证，保证本专项核查意见所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相 ...

对本专项核查意见的出具，本所律师特作如下声明： 1、本所及经办律师依据《公司法》《证券法》《回购指引》等规定及本专项核查 意见出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责 和诚实信用原则，进行了充分的核查验证，保证本专项核查意见所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相应法律责任； 关于宁波永新光学股份有限公司 差异化权益分派事项的专项核查意见 致：宁波永新光学股份有限公司 国浩律师（上海）事务所接受宁波永新光学股份有限公司（以下简称为"永新光 学"或"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司自 律监管指引第 7 号——回购股份》（以下简称"《回购指引》"）等有关法律法规以及 《宁波永新光学股份有限公司章程》（以下简称"《公司章程》"）的规定，按照律师 行业公认的业务标准，道德规范和勤勉尽责的精神，对永新光学差异化权益分派事 项进行了核查并出具本专项核查意见。 国浩律师（上海）事务所 专项核查意见 国浩律师（ ...

证券代码：603297 证券简称：永新光学 公告编号：2025-024 宁波永新光学股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.85元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/13 | － | 2025/6/16 | 2025/6/16 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经宁波永新光学股份有限公司（以下简称"公司"）2025 年 5 月 20 日 的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，扣除拟回购注销的限制性股票 213,800 股 后，在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股 ...

证券代码：603297 证券简称：永新光学 公告编号：2025-024 宁波永新光学股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经宁波永新光学股份有限公司（以下简称"公司"）2025 年 5 月 20 日 的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 每股分配比例 截至股权登记日下午上海证券交易所收市后，扣除拟回购注销的限制性股票 213,800 股 后，在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股东。 A 股每股现金红利0.85元 相关日期 2. 分派对象： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/13 | － | 2025/6/16 | 2025/6/16 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和 ...

Core Insights - Yongxin Optical achieved operating revenue of 892 million yuan in 2024, representing a year-on-year growth of 4.41%. The net profit attributable to shareholders, excluding non-recurring gains and losses, was 185 million yuan, up 14.25% year-on-year [1] - The company plans to focus on its strategic development goals for 2025, emphasizing its competitive advantages in niche markets and deepening its "2+2" business layout, which includes expanding into lidar and medical optics while building on its existing optical microscope and barcode machine vision businesses [1] Business Development - In the lidar sector, Yongxin Optical has been engaged for nearly 10 years, becoming a key partner for leading global companies such as Hesai, TuDatong, and Valeo. The company's lidar optical component business entered large-scale production in 2024, with revenue surpassing 100 million yuan [1] - In the medical optics field, Yongxin Optical aims to replace foreign mid-to-high-end products, focusing on domestic production challenges for endoscopes, surgical microscopes, and high-end pathological diagnostic equipment. The core optical components for endoscopes have seen rapid growth, covering over 70% of major domestic endoscope system manufacturers [2] - The penetration rate of Yongxin Optical's self-developed high-end microscopes in the domestic market has reached 5%, contributing to an increase in the gross margin of its microscope business [2]

电话/TEL: (8621) 5234-1668 传真/FAX: (8621) 5234-1670 关于宁波永新光学股份有限公司 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 Grandall Law Firm (Shanghai) 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 2024年年度股东大会的法律意见书 致：宁波永新光学股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波永新光学股份有限 公司（以下简称"公司"）委托，指派本所律师出席公司 2024 年年度股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国证券法》（以下简 称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门规章 和规范性文件以及《宁波永新光学股份有限公司章程》（以下简称"《公司章程》"） ...

证券代码：603297 证券简称：永新光学 公告编号：2025-023 宁波永新光学股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 96 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 78,615,611 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 70.7289 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由公司联席董事长毛磊先生主持，采用现 场与网络投票相结合的方式召开。本次会议的召集、召开和表决方式符合《公司 (一) 股东大会召开的时间：2025 年 5 月 20 日 (二) 股东大会召开的地点：浙江省宁波高新区木槿路 169 号公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ...

Core Insights - The CT equipment market in China is projected to reach approximately 25.5 billion yuan in 2024, driven by increasing clinical demand due to an aging population and rising chronic disease prevalence [1][20] - The market is expected to maintain rapid growth as investments in healthcare increase and the implementation of hierarchical medical care continues [1][20] Industry Overview - CT, or computed tomography, is a medical imaging technology that utilizes X-rays to create detailed images of the body's internal structures, widely used for diagnosing various diseases [3][7] - The CT equipment industry is characterized by high technical barriers, requiring long-term technological accumulation for both core component development and complete device manufacturing [16] Market Dynamics - The demand for CT equipment is increasing due to the aging population and the growing need for medical examinations, with the number of CT devices in China expected to reach approximately 55,133 units by 2024 [21] - The domestic CT equipment market's localization rate is projected to be around 53% in 2024, with over 66% of sales coming from high-quality domestic brands [23] Competitive Landscape - The CT equipment industry in China exhibits a tiered competitive structure, with leading companies like GE Healthcare, United Imaging, and Siemens dominating the high-end market, while domestic firms are rapidly catching up through technological innovation [26][28] - Companies such as United Imaging and Wandong Medical are focusing on high-performance imaging equipment and innovative solutions to enhance their market presence [28][30] Policy Environment - The Chinese government has implemented strict regulatory frameworks for medical devices, promoting high-quality development and technological innovation in the CT equipment sector [9][11] - Recent policies aim to enhance the regulatory system for medical devices, ensuring safety and effectiveness while fostering innovation and competitiveness in the industry [9][11] Future Trends - The industry is witnessing a shift towards technological innovation and domestic substitution, with local manufacturers making significant strides in core component production and image quality [32] - The demand for CT equipment in grassroots medical institutions is expected to grow, driven by the hierarchical medical care policy and the increasing number of private hospitals [33] - The integration of AI and digital technologies in CT equipment is anticipated to enhance diagnostic capabilities and operational efficiency, aligning with the industry's move towards sustainability and environmental compliance [34]

Core Points - The company held its 2024 Annual General Meeting to discuss various proposals, including the 2025 compensation plan for directors and senior management, and the authorization for the board to issue shares to specific targets [1][2][3] - The company reported a revenue of 892 million yuan in 2024, a 4.41% increase from the previous year, with significant growth in the optical components business [4][6] - The net profit attributable to shareholders for 2024 was 209 million yuan, a decrease of 14.25% compared to the previous year, influenced by increased R&D expenses and the absence of one-time gains from land acquisition [4][5] - The company plans to distribute a cash dividend of 8.50 yuan per 10 shares, totaling approximately 94 million yuan, marking a cash dividend ratio of 45.21%, the highest since its listing [31][32] Meeting Agenda - The meeting was scheduled for May 20, 2025, at 14:30, with a detailed agenda including reports from the board and supervisory committee, financial statements, and various proposals for shareholder approval [1][2] - The meeting included provisions for shareholder participation, allowing for both on-site and online voting [2][3] Financial Performance - The company achieved a total asset value of approximately 2.3 billion yuan by the end of 2024, reflecting a 9.85% increase from the previous year [19][21] - The total liabilities increased by 29.17% to approximately 361 million yuan, primarily due to an increase in short-term borrowings [22][24] - The company’s equity rose by 6.87% to approximately 1.94 billion yuan, with significant changes in stock repurchase obligations and minority interests [24][25] Strategic Initiatives - The company is focusing on enhancing its technological capabilities and market competitiveness through a dual-engine strategy, aiming for high-end scientific instrument production and consumer-oriented optical components [4][6] - A talent development plan is in place to foster a younger management team, with over 60% of mid-to-senior management being under 40 years old [6][15] Governance and Compliance - The board of directors and supervisory committee have adhered to legal and regulatory requirements, ensuring the legality and effectiveness of their operations [11][18] - The company has implemented a stock incentive plan to attract and retain talent, with 72,100 shares granted to 146 employees [12][13]